Low Seroprevalence of SARS-CoV-2 in Rhode Island blood donors during may 2020 as determined using multiple serological assay formats

BMC Infectious Diseases

Joseph W. Hogan¹  Haidee Chen²  Larry L. Luchsinger²  Jenny Yang²  Daniel P. Jin²  Christopher D. Hillyer²  Daniel J. Nesbitt²  Melissa J. Simon³  Matthew Vargas³  Philip A. Chan⁴  Utpala Bandy⁴  Ewa King⁵  Richard C. Huard⁵ 

[1] Department of Biostatistics, Brown University, Providence, RI, USA;New York Blood Center, Lindsley F. Kimball Research Institute, New York, NY, USA;Rhode Island Commerce Corporation, Providence, RI, USA;Rhode Island Department of Health, Providence, RI, USA;Rhode Island Department of Health, Providence, RI, USA;Rhode Island State Health Laboratory, Providence, RI, USA;

关键词: COVID-19;    SARS-CoV-2;    Seroprevalence;    Rhode Island;    Pandemic;    Serology;    Antibody;   

DOI  :  10.1186/s12879-021-06438-4

来源: Springer

【 摘 要 】

BackgroundEpidemic projections and public health policies addressing Coronavirus disease (COVID)-19 have been implemented without data reporting on the seroconversion of the population since scalable antibody testing has only recently become available.MethodsWe measured the percentage of severe acute respiratory syndrome- Coronavirus-2 (SARS-CoV-2) seropositive individuals from 2008 blood donors drawn in the state of Rhode Island (RI). We utilized multiple antibody testing platforms, including lateral flow immunoassays (LFAs), enzyme-linked immunosorbent assays (ELISAs) and high throughput serological assays (HTSAs). To estimate seroprevalence, we utilized the Bayesian statistical method to adjust for sensitivity and specificity of the commercial tests used.ResultsWe report than an estimated seropositive rate of RI blood donors of approximately 0.6% existed in April–May of 2020. Daily new case rates peaked in RI in late April 2020. We found HTSAs and LFAs were positively correlated with ELISA assays to detect antibodies specific to SARS-CoV-2 in blood donors.ConclusionsThese data imply that seroconversion, and thus infection, is likely not widespread within this population. We conclude that IgG LFAs and HTSAs are suitable to conduct seroprevalence assays in random populations. More studies will be needed using validated serological tests to improve the precision and report the kinetic progression of seroprevalence estimates.

【 授权许可】

CC BY